Fresenius Medical Care Analyst Ratings
Fresenius Medical Care Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 39.53% | Truist Securities | $28 → $24 | Maintains | Hold |
| 07/13/2023 | 62.79% | Truist Securities | $26 → $28 | Maintains | Hold |
| 05/10/2023 | 51.16% | Truist Securities | $24 → $26 | Maintains | Hold |
| 04/13/2023 | 39.53% | Truist Securities | $22 → $24 | Maintains | Hold |
| 02/23/2023 | 27.91% | Truist Securities | $17 → $22 | Maintains | Hold |
| 06/22/2022 | 56.98% | Truist Securities | $34 → $27 | Maintains | Hold |
| 11/23/2021 | — | HSBC | Initiates Coverage On | → Hold | |
| 11/17/2021 | 103.49% | RBC Capital | $42 → $35 | Maintains | Sector Perform |
| 11/11/2021 | — | Jefferies | Upgrades | Underperform → Hold | |
| 05/21/2020 | 179.07% | SunTrust Robinson Humphrey | $46 → $48 | Maintains | Buy |
| 05/11/2020 | 167.44% | SunTrust Robinson Humphrey | $42 → $46 | Maintains | Buy |
| 04/13/2020 | 144.19% | SunTrust Robinson Humphrey | $46 → $42 | Maintains | Buy |
| 02/21/2020 | 167.44% | CFRA | $38 → $46 | Upgrades | Hold → Buy |
| 01/21/2020 | — | Jefferies | Upgrades | Hold → Buy | |
| 10/23/2019 | — | Redburn Partners | Downgrades | Buy → Neutral | |
| 08/01/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/20/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 10/26/2018 | — | UBS | Upgrades | Neutral → Buy | |
| 10/18/2018 | — | DZ Bank | Downgrades | Buy → Hold |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2023 年 11 月 10 日 | 39.53% | 信实证券 | 28 美元 → 24 美元 | 维护 | 保持 |
| 07/13/2023 | 62.79% | 信实证券 | 26 美元 → 28 美元 | 维护 | 保持 |
| 05/10/2023 | 51.16% | 信实证券 | 24 美元 → 26 美元 | 维护 | 保持 |
| 04/13/2023 | 39.53% | 信实证券 | 22 美元 → 24 美元 | 维护 | 保持 |
| 02/23/2023 | 27.91% | 信实证券 | 17 美元 → 22 美元 | 维护 | 保持 |
| 06/22/2022 | 56.98% | 信实证券 | 34 美元 → 27 美元 | 维护 | 保持 |
| 11/23/2021 | — | 汇丰银行 | 启动覆盖范围开启 | → 按住 | |
| 11/17/2021 | 103.49% | 加拿大皇家银行资本 | 42 美元 → 35 美元 | 维护 | 行业表现 |
| 11/11/2021 | — | 杰富瑞 | 升级 | 表现不佳 → 持有 | |
| 05/21/2020 | 179.07% | SunTrust 罗宾逊·汉弗莱 | 46 美元 → 48 美元 | 维护 | 购买 |
| 05/11/2020 | 167.44% | SunTrust 罗宾逊·汉弗莱 | 42 美元 → 46 美元 | 维护 | 购买 |
| 2020 年 4 月 13 日 | 144.19% | SunTrust 罗宾逊·汉弗莱 | 46 美元 → 42 美元 | 维护 | 购买 |
| 02/21/2020 | 167.44% | CFRA | 38 美元 → 46 美元 | 升级 | 持有 → 买入 |
| 2020 年 1 月 21 日 | — | 杰富瑞 | 升级 | 持有 → 买入 | |
| 2019 年 10 月 23 日 | — | Redburn 合作伙伴 | 降级 | 买入 → 中性 | |
| 08/01/2019 | — | BTIG | 降级 | 买入 → 中性 | |
| 06/20/2019 | — | 巴克莱 | 升级 | 重量相等 → 超重 | |
| 2018 年 10 月 26 日 | — | 瑞银（UBS） | 升级 | 中性 → 买入 | |
| 10/18/2018 | — | DZ 银行 | 降级 | 买入 → 持有 |
What is the target price for Fresenius Medical Care (FMS)?
费森尤斯医疗（FMS）的目标价格是多少？
The latest price target for Fresenius Medical Care (NYSE: FMS) was reported by Truist Securities on October 11, 2023. The analyst firm set a price target for $24.00 expecting FMS to rise to within 12 months (a possible 39.53% upside). 5 analyst firms have reported ratings in the last year.
Truist Securities于2023年10月11日公布了费森尤斯医疗（纽约证券交易所代码：FMS）的最新目标股价。该分析公司将目标股价定为24.00美元，预计FMS将在12个月内上涨至39.53％（可能上涨39.53％）。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Fresenius Medical Care (FMS)?
费森尤斯医疗（FMS）的最新分析师评级是多少？
The latest analyst rating for Fresenius Medical Care (NYSE: FMS) was provided by Truist Securities, and Fresenius Medical Care maintained their hold rating.
费森尤斯医疗（纽约证券交易所代码：FMS）的最新分析师评级由Truist Securities提供，费森尤斯医疗维持其持仓评级。
When is the next analyst rating going to be posted or updated for Fresenius Medical Care (FMS)?
费森尤斯医疗（FMS）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与费森尤斯医疗的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。费森尤斯医疗的最新评级是在2023年10月11日提交的，因此你应该预计下一个评级将在2024年10月11日左右公布。
Is the Analyst Rating Fresenius Medical Care (FMS) correct?
分析师对费森尤斯医疗（FMS）的评级是否正确？
While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a maintained with a price target of $28.00 to $24.00. The current price Fresenius Medical Care (FMS) is trading at is $17.20, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但费森尤斯医疗（FMS）的最新评级保持不变，目标价为28.00美元至24.00美元。费森尤斯医疗（FMS）目前的交易价格为17.20美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。